Circumvent the Tariff challenges with an agile supply chain Consulting
Supply Chain Ecosystem Analysis now part of DBMR Reports
Global Embolization Particle Market
Market Size in USD Billion
CAGR :
%
USD
2.40 Billion
USD
5.67 Billion
2024
2032
Forecast Period
2025 –2032
Market Size(Base Year)
USD
2.40 Billion
Market Size (Forecast Year)
USD
5.67 Billion
CAGR
11.32
%
Major Markets Players
Sirtex SIR-Spheres Pty Ltd.
Guerbet
Boston Scientific Corporation
Medtronic
Merit Medical Systems
Global Embolization Particle Market Segmentation, By Product Type (Radioembolization Spheres, Microspheres, Drug Eluting Beads (DEBs), PVA Particles and Gelfoam Particles, and Others), Application (Peripheral Vascular Disease, Neurology, Oncology, Urology, and Others), End User (Hospitals, Clinics, Ambulatory Centers, and Others) – Industry Trends and Forecast to 2032
The embolization particle market has seen significant growth due to the increasing prevalence of conditions such as liver cancer, peripheral vascular diseases, and uterine fibroids, which require embolization treatments. Embolization, a procedure where particles are used to block blood flow to certain areas, is increasingly preferred due to its minimally invasive nature and effectiveness. The growing demand for interventional radiology procedures is a key driver of market expansion. Recent advancements include the development of drug-eluting beads (DEBs), which combine embolization with targeted drug delivery for more effective treatments. Moreover, the rising number of hospitals and specialized centers offering embolization procedures, coupled with innovations in embolization particle materials (microspheres, PVA particles), is expected to propel market growth. However, challenges such as the high cost of embolization treatments and limited access in some regions may hinder growth. The market is expected to continue expanding with the increasing adoption of these technologies in both developed and emerging markets.
Embolization Particle Market Size
The global embolization particle market size was valued at USD 2.40 billion in 2024 and is projected to reach USD 5.67 billion by 2032, with a CAGR of 11.32% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Embolization Particle Market Trends
“Development of Personalized Treatments”
The embolization particle market is experiencing significant growth driven by the increasing demand for minimally invasive treatments for conditions such as liver cancer, uterine fibroids, and peripheral vascular diseases. Innovations in embolization particle materials, including drug-eluting beads (DEBs), are transforming treatment approaches by combining embolization with targeted drug delivery. One major trend is the shift toward personalized treatments, where physicians select specific embolization particles based on the patient’s condition and tumor characteristics. Additionally, advancements in microsphere and PVA particle technology are enhancing the precision and effectiveness of embolization procedures. With growing investments in interventional radiology and an expanding patient base, the market for embolization particles is expected to continue its upward trajectory, especially in developed and emerging healthcare markets.
Report Scope and Embolization Particle Market Segmentation
Attributes
Embolization Particle Key Market Insights
Segments Covered
By Product Type: Radioembolization Spheres, Microspheres, Drug Eluting Beads (DEBs), PVA Particles and Gelfoam Particles, and Others
ByApplication: Peripheral Vascular Disease, Neurology, Oncology, Urology, and Others
ByEnd User: Hospitals, Clinics, Ambulatory Centers, and Others
Countries Covered
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Key Market Players
Sirtex SIR-Spheres Pty Ltd. (Australia), Guerbet (France), Boston Scientific Corporation (U.S.), Medtronic (U.S.), Merit Medical Systems (U.S.), BTG (U.K.), KAVYA PHARMA (India), Varian Medical Systems, Inc. (U.S.), Terumo Medical Corporation (Japan), and Cook (U.S.)
Market Opportunities
Increased Incidence of Target Diseases
Rising Healthcare Investments
Value Added Data Infosets
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Embolization Particle Market Definition
Embolization particles are small, biocompatible materials used in medical procedures to block blood flow to a specific area of the body, typically in the treatment of tumors or vascular conditions. These particles are injected into blood vessels through a catheter, where they obstruct the flow of blood to a targeted region, such as a tumor or abnormal vascular structure, leading to tissue ischemia or shrinkage. Embolization particles can vary in composition, including materials such as microspheres, drug-eluting beads, polyvinyl alcohol (PVA) particles, and gel foam, each designed to provide different therapeutic benefits depending on the condition being treated.
Embolization Particle Market Dynamics
Drivers
Rising Incidence of Cancer and Tumors
The rising number of cancer diagnoses, particularly liver and lung cancers, has significantly increased the demand for effective treatments such as embolization particle-based therapies. These treatments are primarily used to target tumors via procedures such as transarterial embolization (TAE) and transarterial chemoembolization (TACE), which are minimally invasive yet highly effective in delivering localized treatment. As these procedures help to block the blood supply to tumors, they prevent cancer cells from growing and spreading. The growing prevalence of cancers, coupled with the effectiveness of embolization techniques, is a key driver of the embolization particle market, expanding its adoption in oncology treatments.
Technological Advancements in Embolization Materials
The development of advanced embolization particles, such as drug-eluting beads and microspheres, is significantly enhancing the precision and effectiveness of embolization treatments. These innovative particles allow for targeted delivery of therapy directly to the tumor site, improving treatment outcomes by minimizing damage to surrounding healthy tissues. Drug-eluting beads, for instance, release chemotherapy drugs over time, providing sustained local treatment. These advancements in embolization technology are expanding the range of applications for embolization techniques, particularly in treating tumors such as those found in the liver and lungs. The growing availability of such advanced particles is a key driver of market growth, increasing their adoption in clinical practice.
Opportunities
Increased Incidence of Target Diseases
The rising global incidence of tumors, including liver cancer, vascular malformations, and uterine fibroids, is driving the demand for embolization procedures. These conditions, particularly liver cancer, are among the leading causes of morbidity and mortality, creating a significant need for effective treatment options. Embolization therapies, which block blood flow to tumors, provide a targeted, minimally invasive approach to treat these diseases. As cancer rates and vascular disorders increase globally, the demand for embolization treatments is expected to grow substantially. This trend represents a key market opportunity for companies involved in the development and distribution of embolization particles, as the need for these treatments continues to expand.
Rising Healthcare Investments
Increasing healthcare spending, especially in emerging economies, is significantly expanding access to advanced medical treatments such as embolization. As these regions experience economic growth, governments and private sectors are investing heavily in healthcare infrastructure, improving facilities, and expanding healthcare coverage. This investment is coupled with enhanced diagnostic capabilities, enabling earlier detection and more effective treatment of conditions such as tumors and vascular diseases. With the rising adoption of minimally invasive procedures, embolization therapies are becoming more accessible to a broader patient population. This trend presents a substantial market opportunity for companies to expand their presence in these growing regions, driving the demand for embolization particles.
Restraints/Challenges
Competition from Alternative Treatments
Other treatment options, such as surgery, radiation therapy, and chemotherapy, continue to be widely used for managing conditions such as tumors and uterine fibroids, posing significant competition to embolization therapies. These traditional treatments have established efficacy and are often preferred due to their long-standing clinical use and familiarity among healthcare providers. As a result, embolization particles, despite being minimally invasive, may face challenges in convincing both patients and doctors to choose them over more conventional options. The competition from these established treatments can slow the adoption of embolization procedures, limiting the overall growth potential of the embolization particle market.
Limited Product Availability
The availability of advanced embolization particles may be constrained in certain regions due to supply chain disruptions, manufacturing challenges, or regulatory barriers. These factors can limit the timely production and distribution of embolization products, particularly in emerging markets where infrastructure and logistics may be underdeveloped. Regulatory hurdles, such as lengthy approval processes and stringent requirements for medical devices, can further delay market entry and restrict access to new embolization therapies. As a result, patients in these regions may not have access to the latest treatments, hindering the overall growth and reach of the embolization particle market.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Embolization Particle Market Scope
The market is segmented on the basis of product type, application, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
Radioembolization Spheres
Microspheres
Drug Eluting Beads (DEBs)
PVA Particles and Gelfoam Particles
Others
Application
Peripheral Vascular Disease
Neurology
Oncology
Urology
Others
End User
Hospitals
Clinics
Ambulatory Centers
Others
Embolization Particle Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, product type, application, and end user referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the embolization particle market due to its robust economic environment and the rapid growth of the healthcare sector. The region's emphasis on research and development, coupled with substantial investments in healthcare infrastructure, drives innovation in advanced diagnostic and treatment technologies. This focus on modernizing healthcare further strengthens the demand for embolization treatments.
The Asia-Pacific region is anticipated to experience substantial growth from 2025 to 2032, driven by a rising patient population, particularly those with cancer, in emerging economies such as India. Increasing healthcare access and awareness in these countries are contributing factors to this growth. As cancer rates rise, the demand for effective treatment options, including embolization, is expected to grow significantly in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Embolization Particle Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Embolization Particle Market Leaders Operating in the Market Are:
Sirtex SIR-Spheres Pty Ltd. (Australia)
Guerbet (France)
Boston Scientific Corporation (U.S.)
Medtronic (U.S.)
Merit Medical Systems (U.S.)
BTG (U.K.)
KAVYA PHARMA (India)
Varian Medical Systems, Inc. (U.S.)
Terumo Medical Corporation (Japan)
Cook (U.S.)
Latest Developments in Embolization Particle Market
In May 2023, Merit Medical Systems, Inc. acquired the BioSentry® Biopsy Tract Sealant System and several dialysis catheter devices from AngioDynamics, Inc. for $100 million in cash. Additionally, Merit Medical made a $32.5 million cash payment to Bluegrass Vascular Technologies, Inc. for the Surfacer® Inside-Out® Access Catheter System. These strategic acquisitions are aimed at expanding Merit’s portfolio in the vascular and biopsy tract management sectors
In June 2023, Terumo Aortic launched its global Post-Approval Study (PAS), known as EXTEND, which centers on the Thoraflex Hybrid device. This device is the only Frozen Elephant Trunk (FET) device approved by the US Food and Drug Administration (FDA) for treating patients with complex aortic arch diseases. The study aims to further evaluate the device's effectiveness and long-term outcomes in this patient population
In December 2022, Sirtex Medical and Grand Pharmaceutical Group Limited received approval from the Chinese National Medical Products Administration for their SIR-Spheres® Y-90 resin microspheres. This milestone marked the first successful selective internal radiation therapy (SIRT) procedure using SIR-Spheres in China. The approval opens up new opportunities for the treatment of liver cancer patients in the region using this advanced therapy
SKU-59609
Get online access to the report on the World's First Market Intelligence Cloud
Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
Frequently Asked Questions
What are the primary segments covered in the Global Embolization Particle Market report?
The market is segmented based on Segmentation, By Product Type (Radioembolization Spheres, Microspheres, Drug Eluting Beads (DEBs), PVA Particles and Gelfoam Particles, and Others), Application (Peripheral Vascular Disease, Neurology, Oncology, Urology, and Others), End User (Hospitals, Clinics, Ambulatory Centers, and Others) – Industry Trends and Forecast to 2032
.
What is the current market size of the Global Embolization Particle Market?
The Global Embolization Particle Market size was valued at USD 2.40 USD Billion in 2024.
What is the expected growth rate of the Global Embolization Particle Market?
The Global Embolization Particle Market is projected to grow at a CAGR of 11.32% during the forecast period of 2025 to 2032.
Who are the key players in the Global Embolization Particle Market?
The major players operating in the market include Sirtex SIR-Spheres Pty Ltd. , Guerbet , Boston Scientific Corporation , Medtronic , Merit Medical Systems , BTG , KAVYA PHARMA , Varian Medical SystemsInc. , Terumo Medical Corporation , and Cook .
Which countries are analyzed in the Global Embolization Particle Market report?
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
Claudio Rondena
Group Business Development & Strategic Marketing Director, C.O.C Farmaceutici SRL
"This morning we were involved in the first part, the data presentation of MKT analysis, selected abstract from your work. The board team was really impressed and very appreciated, as well."
David Manning - Thermo Fisher Scientific
Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice.
Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough.
Your work is much appreciated.
Manager - Market Analytics,
Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Business Development Manager,
(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Business Intelligence and Analytics,
Ipsen Biopharm Limited
We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.
Competition Analyst,
Basler Web
I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.
Marketing Director,
Buhler Group
It was indeed a good experience, would definitely recommend and come back for future prospects.
COO,
A global leader providing Drug Delivery Services
DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.
Marketing Director,
Philips Healthcare
The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.
Product manager,
Fujifilms
Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.
Investor relations,
GE Healthcare
Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.
Market Analyst,
Medincell
We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.
Andrew - Senior Global Marketing Manager,
Medtronic (US)
I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.
Amarildo - Manager, Global Strategic Alignment
MasterCard
We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.
Tor Hammer
Green Nexus LLc
Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects
I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying.
Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.
Yuki Kopyl (Asian Business Development Department)
UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)
Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future